FDA approves cysteamine ophthalmic solution 0.44% for treatment of corneal cystine crystals in cystinosis patients

News
Article

FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44%, a topical ophthalmic therapeutic, developed in partnership with the National Institutes of Health (NIH), for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.